HER2-Positive Patients With High TIL Levels Benefit From Chemo AloneJason M. Broderick
a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) and tislelizumab (TIS) as first-line (1L) therapy for patients (pts) with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (G/GEJC): ...
15.Keun-Wook Lee, et al. Zanidatamab (zani) plus chemotherapy (chemo) and tislelizumab (tis) as first-line (1l) therapy for patients (pts) with advanced HER2-positive (+) gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a phase Ib/II study. ESMO 2023. ...
[29]S Krause,et al.Abstract OT2-07-01:DETECT V/CHEVENDO–Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo-or endocrine therapy in addition with CDK4/6 inhibition in patients with HER2-positive and hormone-receptor positive metastatic breast cancer....
Among HER2-positive breast cancer patients treated with chemotherapy alone, women with high levels of stromal tumor-infiltrating lymphocytes had an 80% lower likelihood of disease recurrence compared to those with lower TIL counts.
[29]S Krause,et al.Abstract OT2-07-01:DETECT V/CHEVENDO–Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo-or endocrine therapy in addition with CDK4/6 inhibition in patients with HER2-positive and hormone-receptor positive metastatic breast cancer...
[12]Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) and tislelizumab (TIS) as first-line (1L) therapy for patients (pts) with advanced HER2-positive gastric/gastroesophageal junction...
[2] Shen L, Chen P, Lu J, et al. Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY...
Abstract P4-15-11: Advanced HER2 positive breast cancer treated with trastuzumab: Is combination with chemotherapy always needed? Randomized phase III trial SAKK 22/99 TChemo) versus the upfront combination of T and chemo (TChemo) in patients with HER2+ advanced breast cancer.Materials and ...
10. Lin Shen,1 Ping Chen, Jin Lu, et al. Trastuzumab deruxtecan in Chinese patients with previously treated HER2-positive locally advanced/metastatic gastric or gastroesophageal junction adenocarcinoma: DESTINY-Gastric06 final analysis. 2024 ESMO Asia.129MO. ...